7D2A Stock Chart & Stats
€0.73
>-€0.01(-0.41%)
At close: 4:00 PM EDT
€0.73
>-€0.01(-0.41%)
Day’s Range― - ―
52-Week Range€0.67 - €1.52
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€88.77M
Enterprise Value€778.04
Total Cash (Recent Filing)€51.79M
Total Debt (Recent Filing)€7.32M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 22, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding99,336,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€18.79M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large equity cushion materially reduce solvency and refinancing risk. This provides durable financial flexibility to fund commercialization, regulatory work and installed-base support over the next 2–6 months despite operational losses, improving runway and strategic optionality.
High Gross MarginsA ~71% gross margin indicates attractive unit economics and pricing power for the Sedaconda franchise. If volumes recover, the company can leverage these margins to drive operating leverage and move toward profitability, making margins a structural strength that supports cash generation long-term.
Proprietary Product With Consumable Recurring RevenueOwning a proprietary inhaled-sedation drug plus consumables creates an installed-base and recurring per-patient revenue. This business model supports durable revenue streams as ICU adoption grows and can create sticky, repeatable demand from hospitals and distributors over multiple quarters.
Bears Say
Sharp Revenue ContractionA 35% TTM revenue decline is a material structural headwind: it reduces fixed-cost absorption, slows installed-base expansion, and impairs channel confidence. Sustained top-line shrinkage undermines the path to profitability even with high gross margins and raises execution risk for commercial plans.
Persistent Negative Operating Cash FlowConsistent negative operating cash flow and deeply negative FCF (~-58.7M TTM) indicate structural cash burn requiring external funding or dramatic margin/volume improvement. This constrains investment in sales/market development and increases dilution or refinancing risk over the coming months.
Ongoing Operating And Net LossesSustained negative EBIT and net margins show the company has not yet converted unit economics into corporate profitability. Negative ROE (~-4.4% TTM) signals capital is not generating returns, prolonging reliance on external capital and limiting long-term shareholder value creation unless trends reverse.
Sedana Medical AB News
7D2A FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was €0.67 and its highest was €1.52 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is €88.77M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Oct 22, 2026 which is in 78 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Jul 17, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.008 by -€0.001.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is >-0.01.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.008. Following the earnings report the stock price went up 0.667%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in DE:7D2A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.